We applied latent class and trajectory modelling to examine whether subgroups of axial spondylarthritis (axSpA) patients report discordant scores for disease activity and mental health symptoms at baseline and after treatment change.

To investigate the relative contribution of cartilage and synovial turnover to predict progression in patients with knee or hip osteoarthritis (OA).

Pharmacological management in the axial spondyloarthritis (axSpA) field has advanced in recent years. Accumulating evidence on long-term efficacy and safety of biological agents targeting TNFa and IL-17, as well as data on JAK inhibitors is now available. Rheumatologists have currently more options for treatment as compared with 20 years ago, but choosing the best therapeutical approach for a single patient remains a challenge. Despite generalized treatment recommendations provided by international societies, patients present with a heterogeneity of symptoms and treatment responses. In the context of personalized medicine, understanding the disease phenotype in combination with extra-musculoskeletal manifestations is a core step for treatment decision making. Beyond disease-related aspects, comorbidities could also be particularly relevant in the selection of the most appropriate drug, given their different efficacy and safety profiles. AxSpA patient's fertility and pregnancy outcomes with regard to therapy also form a consideration, since symptom onset usually falls into the child-bearing age. This article will discuss the selective effect of the approved treatment modalities on the different axSpA manifestations and co-existing conditions.

Diagnostic delay (DD) is well-documented in SpA, particularly in axial disease. This ancillary analysis from the ASAS-PerSpA study estimated DD across SpA entities, considering the presenting disease manifestation, and evaluated factors associated with DD.

Rheumatoid arthritis is a chronic and progressive disease, the most important and common symptom of which is pain. Considering the physical and psychological effects of pain on health and well-being, it seems that finding new methods such as conceptual mapping to teach self-care to patients is important for controlling and reducing pain. This study was conducted to determine the effect of self-care education based on conceptual mapping on the pain severity of patients with rheumatoid arthritis.

We assessed the validity of Patient-Reported Outcome Measurement Information System (PROMIS) for juvenile and adult-onset idiopathic inflammatory myopathies (JIIM/IIM) and determined associations with disease characteristics and assessments.

The objective of this study was to evaluate early damage, and its evolution and prognostic relevance in an inception cohort of patients with Takayasu arteritis (TAK) using the Large Vessel Vasculitis Index of Damage (LVVID).

To assess the value of optical spectral transmission (OST) in detecting joint inflammation in patients with psoriatic arthritis (PsA) and to evaluate correlations of OST with musculoskeletal ultrasound (US) and clinical disease activity markers.

Women with systemic lupus erythematosus (SLE) are at risk for body image (BI) disturbances and its resultant psychological distress (PD). The aim of this study was to examine the effects of self-compassion (SC)-based writing on BI and PD among women with SLE.

Rheumatoid Arthritis (RA) is a prevalent autoimmune disease affecting approximately 84,338 individuals in Egypt. Genetic predispositions, such as the PTPN22 and PADI4 genes, are linked to RA risk. PTPN22, a protein tyrosine phosphatase, a regulator of T-cell receptor signalling and PADI4, which is involved in citrullination, have shown varying levels of association with RA across populations. Studies have been inconclusive regarding their roles in RA susceptibility, progression, and activity.

This study aimed to identify predictors of clinical inertia in SLE management and to evaluate its impact on clinical outcomes.

Patients with SLE have a higher prevalence of cardiometabolic risk factors, metabolic syndrome and cardiovascular disease than the general population. The metabolic dysfunction-associated steatotic liver disease (MASLD), a new term for non-alcohol-related fatty liver disease, has been recognized as an independent predictor of cardiovascular events in the general population. However, the prevalence and associations of MASLD in SLE are uncertain. We aimed to investigate the potential association between MASLD and traditional and disease-related cardiovascular risk factors (CVRFs) in SLE.

Data on patient decision making for people with systemic lupus erythematosus (SLE) are scarce. We previously showed that an evidence-based SLE patient decision aid was more effective than the SLE information pamphlet provided by the American College of Rheumatology in reducing decisional conflict for the choice of immunosuppressive medications in women with lupus nephritis, with higher acceptability and feasibility. The aim of this study was to assess patient outcomes from the implementation of this SLE patient decision aid on disease management in people with SLE.